Evidence map›Paper›PMID 32674599›Full record

ArticleCirculation2020

Stem Cell Pluripotency Genes Klf4 and Oct4 Regulate Complex SMC Phenotypic Changes Critical in Late-Stage Atherosclerotic Lesion Pathogenesis.

Gabriel F Alencar, Katherine M Owsiany, Santosh Karnewar, Katyayani Sukhavasi, Giuseppe Mocci, Anh T Nguyen, Corey M Williams, Sohel Shamsuzzaman, Michal Mokry, Christopher A Henderson and 10 more

Open access · hybridAbstract read
In one paragraph

Article in Circulation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 275 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
275citing papers in PubMed, 3 pooled it
18.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

275 citing papers in PubMed, 3 syntheses or guidelines pooled it, 371 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

215 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 5 countries.

Gabriel F Alencar *Robert M. Berne Cardiovascular Research Center (G.F.A., K.M.O, S.K., A.N., C.M.W., S.S., C.A.H., R.H., R.A.B., C.A.M., E.R.Z., G.K.O.), University of Virginia, Charlottesville.
Katherine M Owsiany *Robert M. Berne Cardiovascular Research Center (G.F.A., K.M.O, S.K., A.N., C.M.W., S.S., C.A.H., R.H., R.A.B., C.A.M., E.R.Z., G.K.O.), University of Virginia, Charlottesville.
Santosh Karnewar *Robert M. Berne Cardiovascular Research Center (G.F.A., K.M.O, S.K., A.N., C.M.W., S.S., C.A.H., R.H., R.A.B., C.A.M., E.R.Z., G.K.O.), University of Virginia, Charlottesville.
Katyayani Sukhavasi *Department of Cardiac Surgery, Tartu University Hospital, Estonia (K.S.).
Giuseppe MocciIntegrated Cardio Metabolic Centre, Department of Medicine, Karolinska Institutet, Karolinska Universitetssjukhuset, Huddinge, Sweden (G.M., V.V., J.B.).
Anh T NguyenRobert M. Berne Cardiovascular Research Center (G.F.A., K.M.O, S.K., A.N., C.M.W., S.S., C.A.H., R.H., R.A.B., C.A.M., E.R.Z., G.K.O.), University of Virginia, Charlottesville.
Corey M WilliamsRobert M. Berne Cardiovascular Research Center (G.F.A., K.M.O, S.K., A.N., C.M.W., S.S., C.A.H., R.H., R.A.B., C.A.M., E.R.Z., G.K.O.), University of Virginia, Charlottesville.
Sohel ShamsuzzamanRobert M. Berne Cardiovascular Research Center (G.F.A., K.M.O, S.K., A.N., C.M.W., S.S., C.A.H., R.H., R.A.B., C.A.M., E.R.Z., G.K.O.), University of Virginia, Charlottesville.
Michal MokryLaboratory of Clinical Chemistry and Hematology, Division Laboratories and Pharmacy (M.M., G.P.), University Medical Center Utrecht, University Utrecht, The Netherlands.
Christopher A HendersonRobert M. Berne Cardiovascular Research Center (G.F.A., K.M.O, S.K., A.N., C.M.W., S.S., C.A.H., R.H., R.A.B., C.A.M., E.R.Z., G.K.O.), University of Virginia, Charlottesville.
Ryan HaskinsRobert M. Berne Cardiovascular Research Center (G.F.A., K.M.O, S.K., A.N., C.M.W., S.S., C.A.H., R.H., R.A.B., C.A.M., E.R.Z., G.K.O.), University of Virginia, Charlottesville.
Richard A BaylisRobert M. Berne Cardiovascular Research Center (G.F.A., K.M.O, S.K., A.N., C.M.W., S.S., C.A.H., R.H., R.A.B., C.A.M., E.R.Z., G.K.O.), University of Virginia, Charlottesville.
Aloke V FinnCVPath Institute, Inc, Gaithersburg, MD (A.V.F.).
Coleen A McNamaraRobert M. Berne Cardiovascular Research Center (G.F.A., K.M.O, S.K., A.N., C.M.W., S.S., C.A.H., R.H., R.A.B., C.A.M., E.R.Z., G.K.O.), University of Virginia, Charlottesville.
Eli R ZunderRobert M. Berne Cardiovascular Research Center (G.F.A., K.M.O, S.K., A.N., C.M.W., S.S., C.A.H., R.H., R.A.B., C.A.M., E.R.Z., G.K.O.), University of Virginia, Charlottesville.
Vamsidhar VenkataIntegrated Cardio Metabolic Centre, Department of Medicine, Karolinska Institutet, Karolinska Universitetssjukhuset, Huddinge, Sweden (G.M., V.V., J.B.).
Gerard PasterkampLaboratory of Clinical Chemistry and Hematology, Division Laboratories and Pharmacy (M.M., G.P.), University Medical Center Utrecht, University Utrecht, The Netherlands.
Johan BjörkegrenIntegrated Cardio Metabolic Centre, Department of Medicine, Karolinska Institutet, Karolinska Universitetssjukhuset, Huddinge, Sweden (G.M., V.V., J.B.).
Stefan BekiranovDepartment of Biochemistry and Molecular Genetics (G.F.A., K.M.O., C.A.H., R.A.B., S.B.), University of Virginia, Charlottesville.
Gary K OwensRobert M. Berne Cardiovascular Research Center (G.F.A., K.M.O, S.K., A.N., C.M.W., S.S., C.A.H., R.H., R.A.B., C.A.M., E.R.Z., G.K.O.), University of Virginia, Charlottesville.
Dr. M.G.R. Educational and Research Institute · INKarolinska University Hospital · SEMACOM (United States) · USUtrecht University · NLCFA Institute · USCVPath Institute · USTartu University Hospital · EE

Funding

BASIC CARDIOVASCULAR RESEARCH TRAINING GRANTT32HL007284 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Brant E Isakson, Gary K Owens · 1985 to 2026
$19.6M
IL1beta signaling in SMCpromotes beneficial changes in late stage atherosclerotic lesion pathogenesisR01HL141425 · NHLBI · UNIVERSITY OF VIRGINIA · PI OWENS, GARY K · 2019 to 2022
$3.1M
Oct4 and Klf4 regulate microvascular SMC-pericyte plasticity, angiogenesis, and metabolic dysfunctionR01HL135018 · NHLBI · UNIVERSITY OF VIRGINIA · PI OWENS, GARY K · 2017 to 2020
$3.1M
Defining SMC phenotypes critical in late stage atherosclerosis pathogenesisR01HL136314 · NHLBI · UNIVERSITY OF VIRGINIA · PI OWENS, GARY K · 2018 to 2021
$3.0M
PDGFbeta Receptor Activation Promotes Atheroprotective Changes in SMC PhenotypeR01HL132904 · NHLBI · UNIVERSITY OF VIRGINIA · PI OWENS, GARY K · 2017 to 2020
$2.6M
Role of IL1b in Regulating SMC and Macrophage Differentiation in AtherosclerosisR01HL121008 · NHLBI · UNIVERSITY OF VIRGINIA · PI OWENS, GARY K · 2014 to 2017
$2.2M
IL1β Promotes Atheroprotective Changes in Late Stage Atherosclerotic LesionsF30HL136188 · NHLBI · UNIVERSITY OF VIRGINIA · PI BAYLIS, RICHARD · 2017 to 2020
$144k
NHLBI NIH HHS F30 HL136188NHLBI NIH HHS R01 HL121008NHLBI NIH HHS R01 HL132904NHLBI NIH HHS R01 HL135018NHLBI NIH HHS R01 HL136314NHLBI NIH HHS R01 HL141425NHLBI NIH HHS T32 HL007284
6 · The paper itself

Abstract

backgroundRupture and erosion of advanced atherosclerotic lesions with a resultant myocardial infarction or stroke are the leading worldwide cause of death. However, we have a limited understanding of the identity, origin, and function of many cells that make up late-stage atherosclerotic lesions, as well as the mechanisms by which they control plaque stability.

methodsWe conducted a comprehensive single-cell RNA sequencing of advanced human carotid endarterectomy samples and compared these with single-cell RNA sequencing from murine microdissected advanced atherosclerotic lesions with smooth muscle cell (SMC) and endothelial lineage tracing to survey all plaque cell types and rigorously determine their origin. We further used chromatin immunoprecipitation sequencing (ChIP-seq), bulk RNA sequencing, and an innovative dual lineage tracing mouse to understand the mechanism by which SMC phenotypic transitions affect lesion pathogenesis.

resultsWe provide evidence that SMC-specific Klf4- versus Oct4-knockout showed virtually opposite genomic signatures, and their putative target genes play an important role regulating SMC phenotypic changes. Single-cell RNA sequencing revealed remarkable similarity of transcriptomic clusters between mouse and human lesions and extensive plasticity of SMC- and endothelial cell-derived cells including 7 distinct clusters, most negative for traditional markers. In particular, SMC contributed to a Myh11

conclusionsTaken together, these results provide evidence that SMC-derived cells within advanced mouse and human atherosclerotic lesions exhibit far greater phenotypic plasticity than generally believed, with Klf4 regulating transition to multiple phenotypes including Lgals3

Indexed as

AnimalsAtherosclerosisFemaleHumansKruppel-Like Factor 4Kruppel-Like Transcription FactorsMaleMiceMice, KnockoutMyocytes, Smooth MuscleOctamer Transcription Factor-3PhenotypePluripotent Stem CellsSequence Analysis, RNAKLF4 protein, humanKlf4 protein, mouseKruppel-Like Factor 4Kruppel-Like Transcription FactorsOctamer Transcription Factor-3Pou5f1 protein, mousecoronary diseasesingle nucleotide polymorphismssmooth muscle cellsmooth muscle differentiationsmooth muscle progenitor cell

Identifiers

PMID32674599
PMCPMC7682794
OpenAlexW3042705713

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.